Profiel
Alison V.
Todd is the founder and currently holds the position of Chief Scientific Officer & General Manager at SpeeDx Pty Ltd.
which she founded in 2009.
She previously worked as a Senior Research Director at Johnson & Johnson Research Pty Ltd.
Dr. Todd received her undergraduate and doctorate degrees from The University of Sydney.
Actieve functies van Alison V. Todd
Bedrijven | Functie | Begin |
---|---|---|
SpeeDx Pty Ltd.
SpeeDx Pty Ltd. BiotechnologyHealth Technology SpeeDx Pty Ltd. is a medical diagnostic company focused on the research, development and commercialization of molecular diagnostic detection technologies. It offers various technologies, including MNAzymes, which are multi-component nucleic acid enzymes composed of DNA to be adapted for sensitive and specific multiplexed detection of various target analytes, as well as catalytically modify substrates producing signals to indicate the presence of target; DNAzymes, which are deoxyribozymes or DNA enzymes to catalyze a repertoire of chemical reactions and are used in the sensor/nanotechnology arena, as well as used for human and animal health; and EzyAmp, an isothermal signal amplification cascade that utilizes restriction enzymes. The company was founded by Elisa E. Mokany and Alison V. Todd in 2009 and is headquartered in Eveleigh, Australia. | Oprichter | 08-06-2011 |
Eerdere bekende functies van Alison V. Todd
Bedrijven | Functie | Einde |
---|---|---|
Johnson & Johnson Research Pty Ltd. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Alison V. Todd
The University of Sydney | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
SpeeDx Pty Ltd.
SpeeDx Pty Ltd. BiotechnologyHealth Technology SpeeDx Pty Ltd. is a medical diagnostic company focused on the research, development and commercialization of molecular diagnostic detection technologies. It offers various technologies, including MNAzymes, which are multi-component nucleic acid enzymes composed of DNA to be adapted for sensitive and specific multiplexed detection of various target analytes, as well as catalytically modify substrates producing signals to indicate the presence of target; DNAzymes, which are deoxyribozymes or DNA enzymes to catalyze a repertoire of chemical reactions and are used in the sensor/nanotechnology arena, as well as used for human and animal health; and EzyAmp, an isothermal signal amplification cascade that utilizes restriction enzymes. The company was founded by Elisa E. Mokany and Alison V. Todd in 2009 and is headquartered in Eveleigh, Australia. | Health Technology |
Johnson & Johnson Research Pty Ltd. |